

EMEA (Europe, Middle East and Africa) Inactivated Vaccine Market Report 2017

<https://marketpublishers.com/r/E4199FB0BD0EN.html>

Date: December 2017

Pages: 100

Price: US\$ 4,000.00 (Single User License)

ID: E4199FB0BD0EN

Abstracts

In this report, the EMEA Inactivated Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Inactivated Vaccine for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Inactivated Vaccine market competition by top manufacturers/players, with Inactivated Vaccine sales volume (K MT), price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including

Astellas Pharma (Japan)

CSL Limited (Australia)

Emergent BioSolutions (U.S.)

GlaxoSmithKline (U.K.)

Johnson & Johnson (U.S.)

MedImmune (U.S.)

Merck & Co (U.S.)

Pfizer (U.S.)

Sanofi Pasteur (France)

Serum Institute of India Pvt (India)

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

By End User

Pediatrics

Adults

By Disease Indication

Pneumococcal

Influenza

HPV

Hepatitis

Rotavirus

DTP

Polio

MMR

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Hospital

Medical Center

Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Inactivated Vaccine Market Report 2017

1 INACTIVATED VACCINE OVERVIEW

1.1 Product Overview and Scope of Inactivated Vaccine

1.2 Classification of Inactivated Vaccine

1.2.1 EMEA Inactivated Vaccine Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 EMEA Inactivated Vaccine Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 Pediatrics

1.2.4 Adults

1.3 EMEA Inactivated Vaccine Market by Application/End Users

1.3.1 EMEA Inactivated Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 Hospital

1.3.3 Medical Center

1.3.4 Others

1.4 EMEA Inactivated Vaccine Market by Region

1.4.1 EMEA Inactivated Vaccine Market Size (Value) Comparison by Region (2012-2022)

1.4.2 Europe Status and Prospect (2012-2022)

1.4.3 Middle East Status and Prospect (2012-2022)

1.4.4 Africa Status and Prospect (2012-2022)

1.5 EMEA Market Size (Value and Volume) of Inactivated Vaccine (2012-2022)

1.5.1 EMEA Inactivated Vaccine Sales and Growth Rate (2012-2022)

1.5.2 EMEA Inactivated Vaccine Revenue and Growth Rate (2012-2022)

2 EMEA INACTIVATED VACCINE COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Inactivated Vaccine Market Competition by Players/Manufacturers

2.1.1 EMEA Inactivated Vaccine Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Inactivated Vaccine Revenue and Share by Players (2012-2017)

2.1.3 EMEA Inactivated Vaccine Sale Price by Players (2012-2017)

2.2 EMEA Inactivated Vaccine (Volume and Value) by Type/Product Category

- 2.2.1 EMEA Inactivated Vaccine Sales and Market Share by Type (2012-2017)
- 2.2.2 EMEA Inactivated Vaccine Revenue and Market Share by Type (2012-2017)
- 2.2.3 EMEA Inactivated Vaccine Sale Price by Type (2012-2017)
- 2.3 EMEA Inactivated Vaccine (Volume) by Application
- 2.4 EMEA Inactivated Vaccine (Volume and Value) by Region
 - 2.4.1 EMEA Inactivated Vaccine Sales and Market Share by Region (2012-2017)
 - 2.4.2 EMEA Inactivated Vaccine Revenue and Market Share by Region (2012-2017)
 - 2.4.3 EMEA Inactivated Vaccine Sales Price by Region (2012-2017)

3 EUROPE INACTIVATED VACCINE (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

- 3.1 Europe Inactivated Vaccine Sales and Value (2012-2017)
 - 3.1.1 Europe Inactivated Vaccine Sales Volume and Growth Rate (2012-2017)
 - 3.1.2 Europe Inactivated Vaccine Revenue and Growth Rate (2012-2017)
- 3.2 Europe Inactivated Vaccine Sales and Market Share by Type
- 3.3 Europe Inactivated Vaccine Sales and Market Share by Application
- 3.4 Europe Inactivated Vaccine Sales Volume and Value (Revenue) by Countries
 - 3.4.1 Europe Inactivated Vaccine Sales Volume by Countries (2012-2017)
 - 3.4.2 Europe Inactivated Vaccine Revenue by Countries (2012-2017)
 - 3.4.3 Germany Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 3.4.4 France Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 3.4.5 UK Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 3.4.6 Russia Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 3.4.7 Italy Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 3.4.8 Benelux Inactivated Vaccine Sales and Growth Rate (2012-2017)

4 MIDDLE EAST INACTIVATED VACCINE (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

- 4.1 Middle East Inactivated Vaccine Sales and Value (2012-2017)
 - 4.1.1 Middle East Inactivated Vaccine Sales Volume and Growth Rate (2012-2017)
 - 4.1.2 Middle East Inactivated Vaccine Revenue and Growth Rate (2012-2017)
- 4.2 Middle East Inactivated Vaccine Sales and Market Share by Type
- 4.3 Middle East Inactivated Vaccine Sales and Market Share by Application
- 4.4 Middle East Inactivated Vaccine Sales Volume and Value (Revenue) by Countries
 - 4.4.1 Middle East Inactivated Vaccine Sales Volume by Countries (2012-2017)
 - 4.4.2 Middle East Inactivated Vaccine Revenue by Countries (2012-2017)
 - 4.4.3 Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2012-2017)

- 4.4.4 Israel Inactivated Vaccine Sales and Growth Rate (2012-2017)
- 4.4.5 UAE Inactivated Vaccine Sales and Growth Rate (2012-2017)
- 4.4.6 Iran Inactivated Vaccine Sales and Growth Rate (2012-2017)

5 AFRICA INACTIVATED VACCINE (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

- 5.1 Africa Inactivated Vaccine Sales and Value (2012-2017)
 - 5.1.1 Africa Inactivated Vaccine Sales Volume and Growth Rate (2012-2017)
 - 5.1.2 Africa Inactivated Vaccine Revenue and Growth Rate (2012-2017)
- 5.2 Africa Inactivated Vaccine Sales and Market Share by Type
- 5.3 Africa Inactivated Vaccine Sales and Market Share by Application
- 5.4 Africa Inactivated Vaccine Sales Volume and Value (Revenue) by Countries
 - 5.4.1 Africa Inactivated Vaccine Sales Volume by Countries (2012-2017)
 - 5.4.2 Africa Inactivated Vaccine Revenue by Countries (2012-2017)
 - 5.4.3 South Africa Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 5.4.4 Nigeria Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 5.4.5 Egypt Inactivated Vaccine Sales and Growth Rate (2012-2017)
 - 5.4.6 Algeria Inactivated Vaccine Sales and Growth Rate (2012-2017)

6 EMEA INACTIVATED VACCINE MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

- 6.1 Astellas Pharma (Japan)
 - 6.1.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.1.2 Inactivated Vaccine Product Type, Application and Specification
 - 6.1.2.1 Product A
 - 6.1.2.2 Product B
 - 6.1.3 Astellas Pharma (Japan) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.1.4 Main Business/Business Overview
- 6.2 CSL Limited (Australia)
 - 6.2.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.2.2 Inactivated Vaccine Product Type, Application and Specification
 - 6.2.2.1 Product A
 - 6.2.2.2 Product B
 - 6.2.3 CSL Limited (Australia) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.2.4 Main Business/Business Overview

6.3 Emergent BioSolutions (U.S.)

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Inactivated Vaccine Product Type, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 GlaxoSmithKline (U.K.)

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Inactivated Vaccine Product Type, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Johnson & Johnson (U.S.)

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Inactivated Vaccine Product Type, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Johnson & Johnson (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 MedImmune (U.S.)

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Inactivated Vaccine Product Type, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 MedImmune (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Merck & Co (U.S.)

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Inactivated Vaccine Product Type, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Merck & Co (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)

- 6.7.4 Main Business/Business Overview
- 6.8 Pfizer (U.S.)
 - 6.8.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.8.2 Inactivated Vaccine Product Type, Application and Specification
 - 6.8.2.1 Product A
 - 6.8.2.2 Product B
 - 6.8.3 Pfizer (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.8.4 Main Business/Business Overview
- 6.9 Sanofi Pasteur (France)
 - 6.9.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.9.2 Inactivated Vaccine Product Type, Application and Specification
 - 6.9.2.1 Product A
 - 6.9.2.2 Product B
 - 6.9.3 Sanofi Pasteur (France) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.9.4 Main Business/Business Overview
- 6.10 Serum Institute of India Pvt (India)
 - 6.10.1 Company Basic Information, Manufacturing Base and Competitors
 - 6.10.2 Inactivated Vaccine Product Type, Application and Specification
 - 6.10.2.1 Product A
 - 6.10.2.2 Product B
 - 6.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
 - 6.10.4 Main Business/Business Overview

7 INACTIVATED VACCINE MANUFACTURING COST ANALYSIS

- 7.1 Inactivated Vaccine Key Raw Materials Analysis
 - 7.1.1 Key Raw Materials
 - 7.1.2 Price Trend of Key Raw Materials
 - 7.1.3 Key Suppliers of Raw Materials
 - 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
 - 7.2.1 Raw Materials
 - 7.2.2 Labor Cost
 - 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Inactivated Vaccine

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 8.1 Inactivated Vaccine Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Inactivated Vaccine Major Manufacturers in 2016
- 8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 9.1 Marketing Channel
 - 9.1.1 Direct Marketing
 - 9.1.2 Indirect Marketing
 - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
 - 9.2.1 Pricing Strategy
 - 9.2.2 Brand Strategy
 - 9.2.3 Target Client
- 9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

- 10.1 Technology Progress/Risk
 - 10.1.1 Substitutes Threat
 - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

11 EMEA INACTIVATED VACCINE MARKET FORECAST (2017-2022)

- 11.1 EMEA Inactivated Vaccine Sales, Revenue and Price Forecast (2017-2022)
 - 11.1.1 EMEA Inactivated Vaccine Sales and Growth Rate Forecast (2017-2022)
 - 11.1.2 EMEA Inactivated Vaccine Revenue and Growth Rate Forecast (2017-2022)
 - 11.1.3 EMEA Inactivated Vaccine Price and Trend Forecast (2017-2022)
- 11.2 EMEA Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.3 Europe Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.4 Middle Eastt Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.5 Africa Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.6 EMEA Inactivated Vaccine Sales Forecast by Type (2017-2022)

11.7 EMEA Inactivated Vaccine Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Inactivated Vaccine

Figure EMEA Inactivated Vaccine Sales Volume (K MT) by Type (2012-2022)

Figure EMEA Inactivated Vaccine Sales Volume Market Share by Type (Product Category) in 2016

Figure Pediatrics Product Picture

Figure Adults Product Picture

Figure EMEA Inactivated Vaccine Sales Volume (K MT) by Application (2012-2022)

Figure EMEA Sales Market Share of Inactivated Vaccine by Application in 2016

Figure Hospital Examples

Table Key Downstream Customer in Hospital

Figure Medical Center Examples

Table Key Downstream Customer in Medical Center

Figure Others Examples

Table Key Downstream Customer in Others

Figure EMEA Inactivated Vaccine Market Size (Million USD) by Region (2012-2022)

Figure Europe Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)

Figure Europe Inactivated Vaccine Revenue (Million USD) Status and Forecast by Countries

Figure Middle East Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)

Figure Middle East Inactivated Vaccine Revenue (Million USD) Status and Forecast by Countries

Figure Africa Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)

Figure Africa Inactivated Vaccine Revenue (Million USD) Status and Forecast by Countries

Figure EMEA Inactivated Vaccine Sales Volume and Growth Rate (2012-2022)

Figure EMEA Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)

Figure EMEA Inactivated Vaccine Market Major Players Product Sales Volume (K MT) (2012-2017)

Table EMEA Inactivated Vaccine Sales Volume (K MT) of Major Players (2012-2017)

Table EMEA Inactivated Vaccine Sales Share by Players (2012-2017)

Figure 2016 Inactivated Vaccine Sales Share by Players

Figure 2017 Inactivated Vaccine Sales Share by Players

Figure EMEA Inactivated Vaccine Market Major Players Product Revenue (Million USD)

(2012-2017)

Table EMEA Inactivated Vaccine Revenue (Million USD) by Players (2012-2017)

Table EMEA Inactivated Vaccine Revenue Share by Players (2012-2017)

Table 2016 EMEA Inactivated Vaccine Revenue Share by Players

Table 2017 EMEA Inactivated Vaccine Revenue Share by Players

Table EMEA Inactivated Vaccine Sale Price (USD/MT) by Players (2012-2017)

Table EMEA Inactivated Vaccine Sales (K MT) and Market Share by Type (2012-2017)

Table EMEA Inactivated Vaccine Sales Share by Type (2012-2017)

Figure Sales Market Share of Inactivated Vaccine by Type (2012-2017)

Figure EMEA Inactivated Vaccine Sales Market Share by Type (2012-2017)

Table EMEA Inactivated Vaccine Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Inactivated Vaccine Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Inactivated Vaccine by Type in 2016

Table EMEA Inactivated Vaccine Sale Price (USD/MT) by Type (2012-2017)

Table EMEA Inactivated Vaccine Sales (K MT) and Market Share by Application (2012-2017)

Table EMEA Inactivated Vaccine Sales Share by Application (2012-2017)

Figure Sales Market Share of Inactivated Vaccine by Application (2012-2017)

Figure EMEA Inactivated Vaccine Sales Market Share by Application in 2016

Table EMEA Inactivated Vaccine Sales (K MT) and Market Share by Region (2012-2017)

Table EMEA Inactivated Vaccine Sales Share by Region (2012-2017)

Figure Sales Market Share of Inactivated Vaccine by Region (2012-2017)

Figure EMEA Inactivated Vaccine Sales Market Share in 2016

Table EMEA Inactivated Vaccine Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Inactivated Vaccine Revenue Share by Region (2012-2017)

Figure Revenue Market Share of Inactivated Vaccine by Region (2012-2017)

Figure EMEA Inactivated Vaccine Revenue Market Share Regions in 2016

Table EMEA Inactivated Vaccine Sales Price (USD/MT) by Region (2012-2017)

Figure Europe Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Europe Inactivated Vaccine Revenue and Growth Rate (2012-2017)

Table Europe Inactivated Vaccine Sales (K MT) by Type (2012-2017)

Table Europe Inactivated Vaccine Market Share by Type (2012-2017)

Figure Europe Inactivated Vaccine Market Share by Type in 2016

Table Europe Inactivated Vaccine Sales (K MT) by Application (2012-2017)

Table Europe Inactivated Vaccine Market Share by Application (2012-2017)

Figure Europe Inactivated Vaccine Market Share by Application in 2016

Table Europe Inactivated Vaccine Sales (K MT) by Countries (2012-2017)
Table Europe Inactivated Vaccine Sales Market Share by Countries (2012-2017)
Figure Europe Inactivated Vaccine Sales Market Share by Countries (2012-2017)
Figure Europe Inactivated Vaccine Sales Market Share by Countries in 2016
Table Europe Inactivated Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Europe Inactivated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Europe Inactivated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Europe Inactivated Vaccine Revenue Market Share by Countries in 2016
Figure Germany Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure France Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure UK Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Russia Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Italy Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Benelux Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Middle East Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Middle East Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Inactivated Vaccine Sales (K MT) by Type (2012-2017)
Table Middle East Inactivated Vaccine Market Share by Type (2012-2017)
Figure Middle East Inactivated Vaccine Market Share by Type (2012-2017)
Table Middle East Inactivated Vaccine Sales (K MT) by Applications (2012-2017)
Table Middle East Inactivated Vaccine Market Share by Applications (2012-2017)
Figure Middle East Inactivated Vaccine Sales Market Share by Application in 2016
Table Middle East Inactivated Vaccine Sales Volume (K MT) by Countries (2012-2017)
Table Middle East Inactivated Vaccine Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Inactivated Vaccine Sales Volume Market Share by Countries in 2016
Table Middle East Inactivated Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Middle East Inactivated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Middle East Inactivated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Middle East Inactivated Vaccine Revenue Market Share by Countries in 2016
Figure Saudi Arabia Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Israel Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure UAE Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Iran Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Africa Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Africa Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Inactivated Vaccine Sales (K MT) by Type (2012-2017)
Table Africa Inactivated Vaccine Sales Market Share by Type (2012-2017)
Figure Africa Inactivated Vaccine Sales Market Share by Type (2012-2017)
Figure Africa Inactivated Vaccine Sales Market Share by Type in 2016
Table Africa Inactivated Vaccine Sales (K MT) by Application (2012-2017)
Table Africa Inactivated Vaccine Sales Market Share by Application (2012-2017)
Figure Africa Inactivated Vaccine Sales Market Share by Application (2012-2017)
Table Africa Inactivated Vaccine Sales Volume (K MT) by Countries (2012-2017)
Table Africa Inactivated Vaccine Sales Market Share by Countries (2012-2017)
Figure Africa Inactivated Vaccine Sales Market Share by Countries (2012-2017)
Figure Africa Inactivated Vaccine Sales Market Share by Countries in 2016
Table Africa Inactivated Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Africa Inactivated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Africa Inactivated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Africa Inactivated Vaccine Revenue Market Share by Countries in 2016
Figure South Africa Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Nigeria Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Egypt Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Algeria Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Table Astellas Pharma (Japan) Inactivated Vaccine Basic Information List
Table Astellas Pharma (Japan) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)
Table CSL Limited (Australia) Inactivated Vaccine Basic Information List
Table CSL Limited (Australia) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Emergent BioSolutions (U.S.) Inactivated Vaccine Basic Information List

Table Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table GlaxoSmithKline (U.K.) Inactivated Vaccine Basic Information List

Table GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Johnson & Johnson (U.S.) Inactivated Vaccine Basic Information List

Table Johnson & Johnson (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure Johnson & Johnson (U.S.) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Johnson & Johnson (U.S.) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure Johnson & Johnson (U.S.) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table MedImmune (U.S.) Inactivated Vaccine Basic Information List

Table MedImmune (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure MedImmune (U.S.) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure MedImmune (U.S.) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure MedImmune (U.S.) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Merck & Co (U.S.) Inactivated Vaccine Basic Information List

Table Merck & Co (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure Merck & Co (U.S.) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Merck & Co (U.S.) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure Merck & Co (U.S.) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Pfizer (U.S.) Inactivated Vaccine Basic Information List

Table Pfizer (U.S.) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure Pfizer (U.S.) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Pfizer (U.S.) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure Pfizer (U.S.) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Sanofi Pasteur (France) Inactivated Vaccine Basic Information List

Table Sanofi Pasteur (France) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure Sanofi Pasteur (France) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Sanofi Pasteur (France) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure Sanofi Pasteur (France) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Serum Institute of India Pvt (India) Inactivated Vaccine Basic Information List

Table Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)

Figure Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K MT) and Growth Rate (2012-2017)

Figure Serum Institute of India Pvt (India) Inactivated Vaccine Sales Market Share in EMEA (2012-2017)

Figure Serum Institute of India Pvt (India) Inactivated Vaccine Revenue Market Share in EMEA (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Inactivated Vaccine

Figure Manufacturing Process Analysis of Inactivated Vaccine

Figure Inactivated Vaccine Industrial Chain Analysis

Table Raw Materials Sources of Inactivated Vaccine Major Manufacturers in 2016

Table Major Buyers of Inactivated Vaccine

Table Distributors/Traders List

Figure EMEA Inactivated Vaccine Sales (K MT) and Growth Rate Forecast (2017-2022)

Figure EMEA Inactivated Vaccine Revenue and Growth Rate Forecast (2017-2022)

Figure EMEA Inactivated Vaccine Price (USD/MT) and Trend Forecast (2017-2022)

Table EMEA Inactivated Vaccine Sales (K MT) Forecast by Region (2017-2022)

Figure EMEA Inactivated Vaccine Sales Market Share Forecast by Region (2017-2022)

Table EMEA Inactivated Vaccine Revenue (Million USD) Forecast by Region
(2017-2022)

Figure EMEA Inactivated Vaccine Revenue Market Share Forecast by Region
(2017-2022)

Table Europe Inactivated Vaccine Sales (K MT) Forecast by Countries (2017-2022)

Figure Europe Inactivated Vaccine Sales Market Share Forecast by Countries
(2017-2022)

Table Europe Inactivated Vaccine Revenue (Million USD) Forecast by Countries
(2017-2022)

Figure Europe Inactivated Vaccine Revenue Market Share Forecast by Countries
(2017-2022)

Table Middle East Inactivated Vaccine Sales (K MT) Forecast by Countries (2017-2022)

Figure Middle East Inactivated Vaccine Sales Market Share Forecast by Countries
(2017-2022)

Table Middle East Inactivated Vaccine Revenue (Million USD) Forecast by Countries
(2017-2022)

Figure Middle East Inactivated Vaccine Revenue Market Share Forecast by Countries
(2017-2022)

Table Africa Inactivated Vaccine Sales (K MT) Forecast by Countries (2017-2022)

Figure Africa Inactivated Vaccine Sales Market Share Forecast by Countries
(2017-2022)

Table Africa Inactivated Vaccine Revenue (Million USD) Forecast by Countries
(2017-2022)

Figure Africa Inactivated Vaccine Revenue Market Share Forecast by Countries
(2017-2022)

Table EMEA Inactivated Vaccine Sales (K MT) Forecast by Type (2017-2022)

Figure EMEA Inactivated Vaccine Sales Market Share Forecast by Type (2017-2022)

Table EMEA Inactivated Vaccine Sales (K MT) Forecast by Application (2017-2022)

Figure EMEA Inactivated Vaccine Sales Market Share Forecast by Application
(2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

I would like to order

Product name: EMEA (Europe, Middle East and Africa) Inactivated Vaccine Market Report 2017

Product link: <https://marketpublishers.com/r/E4199FB0BD0EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E4199FB0BD0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970